Intended Audience:
The program is intended for thrombosis specialists, oncologists, hematologists, coagulation experts, cardiologists, surgeons, and related disciplines.

Registration:
Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:
Supported by an independent educational grant from Eisai, Inc.

Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials


Faculty Disclosures:

Ajay Kakkar, MBBS, PhD, FRCS
Grants/research support: sanofi-aventis, AstraZeneca, Pfizer
Consultant: Pfizer, sanofi-aventis

Craig M. Kessler, MD
Grants/research support: sanofi-aventis, Eisai, GlaxoSmithKline, Octapharma
Consultant: sanofi-aventis, Eisai, NovoNordisk

Alex C. Spyropoulos, MD, FACP, FCCP
Grants/research support: sanofi-aventis, AstraZeneca
Consultant: sanofi-aventis, AstraZeneca

Samuel Z. Goldhaber, MD
Grant/Research Support: sanofi-aventis, GSK, Eisai


Program Faculty:

Program Chairman
 Ajay Kakkar, MBBS, PhD, FRCS
Head of the Centre for Surgical Sciences
Barts and the London
Queen Mary's School of Medicine and Dentistry
Thrombosis Research Institute
London, UK

Distinguished Presenters
Craig M. Kessler, MD
Professor of Medicine and Pathology
Georgetown University Medical Center
Director of the Division of Coagulation
Department of Laboratory Medicine
Washington, DC

Alex C. Spyropoulos, MD, FACP, FCCP
Chair, Department of Clinical Thrombosis
Lovelace Medical Center
Clinical Associate Professor of Medicine
University of New Mexico
Albuquerque, New Mexico

Distinguished Panel Member, Consultant, and Visiting Professor
Samuel Z. Goldhaber, MD
Professor of Medicine, Cardiovascular Division
Harvard Medical School
Director, Venous Thromboembolism
Research Group
Director, Anticoagulation Service
Brigham and Women's Hospital
Boston, MA


Educational Objectives:

•Clinicians will review recent trials, research, and expert analysis of issues focused on thrombosis and cancer.

•Clinicians will specify strategies for risk-directed prophylaxis against DVT in at risk patients with cancer.

•Clinicians will explain how to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT.

•Clinicians will describe how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis.

•Clinicians will review landmark clinical trials focusing on DVT prophylaxis in patients with cancer.

• Clinicians will explain how to appropriately use the range of pharmacologic options available for thrombosis management in patients with malignancy.